Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Immune Thrombocytopenia (ITP): later-stage trial registry
1 of 3 indexed Primary Immune Thrombocytopenia (ITP) trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Primary Immune Thrombocytopenia (ITP): 3 US clinical trials tracked, 1 recruiting.
Primary Immune Thrombocytopenia (ITP) is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition primary-immune-thrombocytopenia-itp
OPEN 1 | RECR 33% | LATE 2 | EARLY 1 | RANK #5209 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Primary Immune Thrombocytopenia (ITP) lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Immune Thrombocytopenia (ITP) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Immune Thrombocytopenia (ITP) is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia
argenx
NCT06544499
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
Novartis Pharmaceuticals
NCT05653349
A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies
Novartis Pharmaceuticals
NCT05885555
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Immune Thrombocytopenia (ITP) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Immune Thrombocytopenia (ITP) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Immune Thrombocytopenia (ITP) page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Primary Immune Thrombocytopenia (ITP) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Novartis Pharmaceuticals sponsors the most Primary Immune Thrombocytopenia (ITP) trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Immune Thrombocytopenia (ITP) condition card totals 3 registered trials; most-linked intervention Ianalumab; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.